The predictive role in terms of pathological response and prognostic role of biomarkers such as GST-π, p53, bcl-2 and bax expression, immuno- histochemically detected, and of the S-phase cell fraction, autoradiographically determined as thymidine labeling index (TLI), were investigated within a prospective randomized phase III clinical trial on squamous-cell carcinoma of the oral cavity, including surgery or primary chemotherapy (PCT), which foresaw the prospective determination of biological markers. Pathological response was defined as the achievement after PCT of a pathological complete remission or the presence of microresidual disease. The study was performed on tumors obtained from a series of 100 previously untreated patients with resectable T2-4N0-2M0 carcinoma. All biomarkers were unrelated, except for an inverse relation between TLI and GST-π and a direct relation between bcl-2 and bax expression. In patients treated with surgery alone, 3-year disease-free survival (DFS) appeared to be weakly, but not significantly, related only to GST-π and p53 expression. In patients treated with PCT, pathological response and DFS were independent of p53 expression and cell proliferation. Conversely, low GST-π and bax expression were indicative of pathological response but lost relevance as predictors of DFS, whereas absence of bcl-2 was associated with high probability of 3-year DFS in the overall series as well as in non-responding patients. Within this latter sub-set, all patients with bcl-2-positive tumors relapsed within I year of surgery, whereas a 60% probability of 3-year DFS was observed for patients with bcl-2-negative tumors (p - 0.02). This interim analysis appears to indicate that some biofunctional markers can provide information on pathological response to PCT and could help in understanding treatment efficacy at a cellular level.

Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers / A. Costa, L. Licitra, S. Veneroni, M.G. Daidone, C. Grandi, R. Cavina, R. Molinari, R. Silvestrini. - In: INTERNATIONAL JOURNAL OF CANCER. - ISSN 0020-7136. - 79:6(1998 Dec 18), pp. 619-623.

Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers

L. Licitra;
1998

Abstract

The predictive role in terms of pathological response and prognostic role of biomarkers such as GST-π, p53, bcl-2 and bax expression, immuno- histochemically detected, and of the S-phase cell fraction, autoradiographically determined as thymidine labeling index (TLI), were investigated within a prospective randomized phase III clinical trial on squamous-cell carcinoma of the oral cavity, including surgery or primary chemotherapy (PCT), which foresaw the prospective determination of biological markers. Pathological response was defined as the achievement after PCT of a pathological complete remission or the presence of microresidual disease. The study was performed on tumors obtained from a series of 100 previously untreated patients with resectable T2-4N0-2M0 carcinoma. All biomarkers were unrelated, except for an inverse relation between TLI and GST-π and a direct relation between bcl-2 and bax expression. In patients treated with surgery alone, 3-year disease-free survival (DFS) appeared to be weakly, but not significantly, related only to GST-π and p53 expression. In patients treated with PCT, pathological response and DFS were independent of p53 expression and cell proliferation. Conversely, low GST-π and bax expression were indicative of pathological response but lost relevance as predictors of DFS, whereas absence of bcl-2 was associated with high probability of 3-year DFS in the overall series as well as in non-responding patients. Within this latter sub-set, all patients with bcl-2-positive tumors relapsed within I year of surgery, whereas a 60% probability of 3-year DFS was observed for patients with bcl-2-negative tumors (p - 0.02). This interim analysis appears to indicate that some biofunctional markers can provide information on pathological response to PCT and could help in understanding treatment efficacy at a cellular level.
S-transferase-PI; squamous-cell carcinomas; prognostic-significance; ovarian-carcinoma; neck-cancer; expression; P53; BCL-2; radiotherapy; head
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Biological markers .pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 183.78 kB
Formato Adobe PDF
183.78 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/579977
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 29
social impact